84 related articles for article (PubMed ID: 7775959)
1. Follow-up of antibody responses to human papillomavirus type 16 E7 in patients treated for cervical carcinoma.
Baay MF; Duk JM; Burger MP; de Bruijn HW; Stolz E; Herbrink P
J Med Virol; 1995 Mar; 45(3):342-7. PubMed ID: 7775959
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune response against proteins E6 and E7 in cervical carcinoma patients positive for human papilloma virus type 16 during treatment and follow-up.
Baay MF; Duk JM; Burger MP; de Bruijn HW; Stolz E; Herbrink P
Eur J Clin Microbiol Infect Dis; 1999 Feb; 18(2):126-32. PubMed ID: 10219577
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to human papillomavirus type 16 E7 related to clinicopathological data in patients with cervical carcinoma.
Baay MF; Duk JM; Burger MP; Walboomers J; ter Schegget J; Groenier KH; de Bruijn HW; Stolz E; Herbrink P
J Clin Pathol; 1995 May; 48(5):410-4. PubMed ID: 7629285
[TBL] [Abstract][Full Text] [Related]
4. Pre- and posttreatment serum antibody responses to HPV 16 E2 and HSV 2 ICP8 proteins in women with cervical carcinoma.
Lehtinen M; Leminen A; Kuoppala T; Tiikkainen M; Lehtinen T; Lehtovirta P; Punnonen R; Vesterinen E; Paavonen J
J Med Virol; 1992 Jul; 37(3):180-6. PubMed ID: 1331306
[TBL] [Abstract][Full Text] [Related]
5. Comparison of peptide enzyme-linked immunosorbent assay and radioimmunoprecipitation assay with in vitro-translated proteins for detection of serum antibodies to human papillomavirus type 16 E6 and E7 proteins.
Sun Y; Shah KV; Müller M; Muñoz N; Bosch XF; Viscidi RP
J Clin Microbiol; 1994 Sep; 32(9):2216-20. PubMed ID: 7529250
[TBL] [Abstract][Full Text] [Related]
6. Serum antibody against unfused recombinant E7 protein of human papillomavirus type 16 in cervical cancer patients.
Fujii T; Matsushima Y; Yajima M; Sugimura T; Terada M
Jpn J Cancer Res; 1995 Jan; 86(1):28-34. PubMed ID: 7737906
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of serum antibodies to human papillomavirus-16 E4 and E7 peptides in cervical cancer.
Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Gallee MP; Hart AA; Müller M; Trimbos JB; Helmerhorst TJ
Cancer; 1994 Oct; 74(8):2307-13. PubMed ID: 7922982
[TBL] [Abstract][Full Text] [Related]
8. E6 and E7 Antibody Levels Are Potential Biomarkers of Recurrence in Patients with Advanced-Stage Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma.
Spector ME; Sacco AG; Bellile E; Taylor JMG; Jones T; Sun K; Brown WC; Birkeland AC; Bradford CR; Wolf GT; Prince ME; Moyer JS; Malloy K; Swiecicki P; Eisbruch A; McHugh JB; Chepeha DB; Rozek L; Worden FP
Clin Cancer Res; 2017 Jun; 23(11):2723-2729. PubMed ID: 27872102
[No Abstract] [Full Text] [Related]
9. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
de Gruijl TD; Bontkes HJ; Stukart MJ; Walboomers JM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
J Gen Virol; 1996 Sep; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
[TBL] [Abstract][Full Text] [Related]
10. Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients.
Nindl I; Benitez-Bribiesca L; Berumen J; Farmanara N; Fisher S; Gross G; Lopez-Carillo L; Müller M; Tommasino M; Vazquez-Curiel A
Arch Virol; 1994; 137(3-4):341-53. PubMed ID: 7524466
[TBL] [Abstract][Full Text] [Related]
11. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia.
Zumbach K; Kisseljov F; Sacharova O; Shaichaev G; Semjonova L; Pavlova L; Pawlita M
Int J Cancer; 2000 Feb; 85(3):313-8. PubMed ID: 10652419
[TBL] [Abstract][Full Text] [Related]
12. Expression of human papillomavirus type 16 E7 protein by recombinant baculovirus and use for the detection of E7 antibodies in sera from cervical carcinoma patients.
Stacey SN; Ghosh A; Bartholomew JS; Tindle RW; Stern PL; Mackett M; Arrand JR
J Med Virol; 1993 May; 40(1):14-21. PubMed ID: 7685808
[TBL] [Abstract][Full Text] [Related]
13. Identification of seroreactive epitopes of human papillomavirus type 18 E7 protein by synthetic peptides.
Krchnák V; Pistĕk T; Vágner J; Suchánková A; Kañka J; Ritterová L; Vonka V
Acta Virol; 1993 Oct; 37(5):395-402. PubMed ID: 7514354
[TBL] [Abstract][Full Text] [Related]
14. Association of the antibodies against human papillomavirus 16 E4 and E7 proteins with cervical cancer positive for human papillomavirus DNA.
Onda T; Kanda T; Zanma S; Yasugi T; Watanabe S; Kawana T; Ueda K; Yoshikawa H; Taketani Y; Yoshiike K
Int J Cancer; 1993 Jun; 54(4):624-8. PubMed ID: 8390409
[TBL] [Abstract][Full Text] [Related]
15. Independent association of antibodies against human papillomavirus type 16 E1/E4 and E7 proteins with cervical cancer.
Kanda T; Onda T; Zanma S; Yasugi T; Furuno A; Watanabe S; Kawana T; Sugase M; Ueda K; Sonoda T
Virology; 1992 Oct; 190(2):724-32. PubMed ID: 1325704
[TBL] [Abstract][Full Text] [Related]
16. Identification of antibodies against human papillomavirus type 16 E6 and E7 proteins in sera of patients with cervical neoplasias.
Sasagawa T; Inoue M; Tanizawa O; Yutsudo M; Hakura A
Jpn J Cancer Res; 1992 Jul; 83(7):705-13. PubMed ID: 1325428
[TBL] [Abstract][Full Text] [Related]
17. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of serum IgG antibodies for the E7 and L2 proteins of human papillomavirus type 16 in cervical cancer patients and controls.
Paez CG; Yaegashi N; Sato S; Yajima A
Tohoku J Exp Med; 1993 Jun; 170(2):113-21. PubMed ID: 8266324
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients.
Bleul C; Müller M; Frank R; Gausepohl H; Koldovsky U; Mgaya HN; Luande J; Pawlita M; ter Meulen J; Viscidi R
J Clin Microbiol; 1991 Aug; 29(8):1579-88. PubMed ID: 1722219
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later.
Lehtinen M; Pawlita M; Zumbach K; Lie K; Hakama M; Jellum E; Koskela P; Luostarinen T; Paavonen J; Pukkala E; Sigstad E; Thoresen S; Dillner J
Am J Obstet Gynecol; 2003 Jan; 188(1):49-55. PubMed ID: 12548195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
